Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to eliminate rectal tumors before surgery

NCT ID NCT07104604

Recruiting now Disease control Sponsor: Affiliated Cancer Hospital of Shantou University Medical College Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether adding a new form of chemotherapy (liposomal irinotecan) to standard radiotherapy, immunotherapy (tislelizumab), and another chemotherapy (capecitabine) can make advanced rectal cancers disappear before surgery. The study enrolls adults aged 18–75 with a specific type of locally advanced rectal cancer (pMMR) that has high-risk features. The main goal is to see how many patients achieve complete remission—no sign of cancer after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of radiotherapy, tislelizumab (an immunotherapy), liposomal irinotecan (a chemotherapy), and capecitabine (a chemotherapy)
What this could lead to
If successful, this combination could increase the chance of complete tumor disappearance before surgery, potentially allowing more patients to avoid permanent colostomy and improving long-term outcomes.
What could go wrong
This is a small, early-phase trial (51 participants) testing a new drug formulation (liposomal irinotecan) in a specific patient group, so results may not apply broadly. The combination also carries risks of side effects from chemotherapy, immunotherapy, and radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED MID-LOWER RECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECTAL CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shantou University Medical College Cancer Hospital

    RECRUITING

    Shantou, Guangdong, 515000, China

  • The First Affiliated Hospital of Shantou University Medical College

    NOT_YET_RECRUITING

    Shantou, Guangdong, 515041, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.